)
)
)
Synklino
Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class breakthrough drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. Following recent regulatory approval, SYN002 is set to enter clinical development in kidney transplantation in in the coming months.
Speakers
What is your next catalyst (value inflection) update?
Clinical phase 1 data, safety, Pk and potential efficacy signal
Year Founded
2017
Lead Product in Development
SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1 (SYN002)
CEO/Top Company Official
Thomas Kledal
When you expect your next catalyst update?
Spring/summer 2026, initial readout from phase 1 clinical trial
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
